CLINICAL EVIDENCE THROUGH TRIALS
Clinical Safety and Efficacy of an At-Home, Dual Wavelength Red Light Hair Growth System in Subjects with Androgenetic Alopecia. (Sinclair, 2020)
81 subjects were paired with a Bluetooth-connected mobile app (LED system) or a sham comparator device with a similar user experience through the mobile app to track daily treatment compliance between both groups. Device usage was fixed at once daily, 10-minute treatment durations for a period of 26 weeks. The trial population consisted of adult men and women between 18 and 65 years of age with a diagnosis of androgenetic alopecia, consistent with males who have Norwood Hamilton Classification IIa to V patterns of hair loss and females who have Ludwig-Savin Scale I-1 to I-4, II -1, II-2 or frontal.
Summary: After 16 weeks, subjects that were treated with the dual wavelength red light device and were at least 80% compliant (n=18) had a mean change of 26.3 more hairs per cm² compared to those participants who wore a sham cap, identical in appearance but received no light therapy (n=18).
INCREASE IN HAIR COUNT COMPARISON
(640nm) LED versus:
Laser Hair Growth Device - (Jimenez et al.) Efficacy and Safety of a Low-level Laser Device in the Treatment of Male and Female Pattern Hair Loss: A Multicenter, Randomized, Sham Device-controlled, Double-blind Study. American Journal of Clinical Dermatology 2014. PubMed Reference.
Minoxidil: (Olsen et al.) A multicenter, randomised, placebo-controlled, double-blind clinical trial of a novel formulation of 5% Minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology 2007. PubMed Reference.
Finasteride: (Leyden et al.) Finasteride in the treatment of men with frontal male pattern hair loss. Journal of the American Academy of Dermatology 1999. PubMed Reference.